COMPASS Pathways plc (CMPS)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with CMPS?
Powered by Yahoo ScoutCOMPASS Pathways is approaching a key clinical and regulatory phase for COMP360, its synthetic psilocybin program for treatment-resistant depression. The company is scheduled to report third-quarter results on November 3, 2026, while upcoming clinical presentations and a planned rolling NDA submission could shape investor expectations.
- Previous Close
12.28 - Open
12.37 - Bid 8.83 x 200
- Ask 15.59 x 200
- Day's Range
12.09 - 12.50 - 52 Week Range
4.88 - 15.87 - Volume
607,791 - Avg. Volume
2,660,595 - Market Cap (intraday)
1.681B - Beta (5Y Monthly) 2.56
- PE Ratio (TTM)
-- - EPS (TTM)
-3.76 - Earnings Date Nov 3, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
23.75 - Zacks Rating Neutral
Recent News
View MorePerformance Overview
Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (current)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-29.08%
-
Return on Equity (ttm)
-319.07%
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-394.19M
-
Diluted EPS (ttm)
-3.76
Balance Sheet and Cash Flow
-
Total Cash (mrq)
433.3M
-
Total Debt/Equity (mrq)
64.62%
-
Levered Free Cash Flow (ttm)
249.95M
